Melior Discovery

What Melior Discovery does

Melior Discovery is a privately held preclinical contract research organization (CRO) founded in 2005 and headquartered in Exton, Pennsylvania, specializing in in vivo pharmacology services for pharmaceutical and biotechnology clients. The company operates three proprietary phenotypic screening platforms — theraTRACE® (general drug repositioning/repurposing across ~40 animal models in 14 therapeutic areas), opioidTRACE® (analgesic profiling including abuse liability), and immuno-theraTRACE™ (oncology and immune-modulating agents) — supported by a catalog of more than 150 validated rat and mouse disease models and custom model development capabilities. Its core methodological differentiator is multiplexing, which evaluates compounds across multiple disease models in a single animal cohort, reducing animal, FTE, and test-article requirements versus running models independently.

The company generates revenue primarily through per-project fee-for-service engagements and FTE-based long-term collaborative partnerships with pharmaceutical clients; secondary revenue comes from milestone and royalty payments on out-licensed repositioned drug candidates developed through sister companies Melior Pharmaceuticals I and Melior Pharmaceuticals II (notably MLR-1023/tolimidone licensed to Bukwang Pharmaceutical in 2013 and armesocarb licensed to Adhera Therapeutics in 2021). Go-to-market is exclusively direct enterprise sales with scientific consultation, targeting top-10 global pharmaceutical companies (Pfizer, Merck, AstraZeneca, Johnson & Johnson, GSK, Eli Lilly, Biogen, Takeda, Teva, Boehringer Ingelheim, Daiichi Sankyo, Lundbeck) alongside hundreds of virtual and underfunded biotechnology companies, plus select academic and non-profit institutions. The company is DEA-licensed for Schedule I-V controlled substances and AAALAC-accredited, holds the 2024 CRO of the Year recognition from Life Sciences Review, and reports that 100% of partners requiring additional work have returned for further engagements.

Name

Melior Discovery

Legal name

Melior Discovery, Inc.

Website

https://meliordiscovery.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Melior Discovery is a private preclinical CRO founded in 2005 that provides in vivo pharmacology services and proprietary phenotypic screening platforms (theraTRACE®, opioidTRACE®, immuno-theraTRACE™) to top-10 pharmaceutical companies and biotechs, using multiplexing of 150+ validated animal models across 14 therapeutic areas.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAAAB

Preclinical CROs (Discovery/Pharmacology/DMPK)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAL

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAIALAA

Drug Discovery (Target ID/Validation & Hit Discovery)

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

• In vivo pharmacology services
• Drug repositioning screening
• Preclinical CRO services
• Animal disease models
• Phenotypic screening platforms

Headquarters

HQ city

Exton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services (Fee-for-Service): Melior offers per-project fee-for-service engagements for in vivo pharmacology studies, disease models, and phenotypic screening services. Pricing varies depending on the model and number of groups, with significant discounts offered for increasing work volume. This is the primary revenue stream.
2. FTE-Based Long-Term Partnerships: Many short-term fee-for-service engagements evolve into long-term FTE (full-time equivalent) based partnerships. These arrangements provide economies of scale passed on to partners, representing a recurring revenue component.
3. Collaborative Research / Drug Repositioning Partnerships: Melior offers its theraTRACE platform on a collaborative research basis. The company also builds its own pipeline through Melior Pharmaceuticals and has out-licensed drug candidates, generating milestone and royalty revenue.
4. Out-licensing of Drug Candidates: Melior has out-licensed drug candidates discovered through its phenotypic screening platform, including MLR-1023 (licenses to Bukwang Pharmaceutical) and armesocarb (licenses to Adhera Therapeutics), generating licensing and milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Melior Discovery is a contract research organization (CRO) that provides preclinical in vivo pharmacology services for drug repositioning and repurposing. It screens client compounds across proprietary multiplexed animal disease models using its theraTRACE®, opioidTRACE®, and immuno-theraTRACE™ platforms spanning 14 therapeutic areas, delivering preclinical efficacy data, study design, execution, and analysis to pharmaceutical and biotechnology clients.

Product overview

Melior Discovery is a Contract Research Organization (CRO) offering in vivo pharmacology services with a portfolio of three proprietary phenotypic screening platforms: theraTRACE® (general drug repositioning/repurposing), opioidTRACE® (analgesic profiling), and immuno-theraTRACE™ (oncology screening). The company's core offering is built on its proprietary multiplexing approach that allows evaluation of compounds across approximately 40 animal models simultaneously for a fraction of traditional costs. Supporting these platforms is a catalog of more than 80 validated in vivo disease models spanning 14 therapeutic areas, with custom model development capabilities. Services are available as contract research or collaborative research arrangements.

Differentiator

Problem solved

Functional benefit

Brands

• theraTRACE®: Proprietary phenotypic screening platform for drug repositioning, drug repurposing, and indications discovery, comprising approximately 40 animal models across 14 therapeutic areas.
• opioidTRACE®
• immuno-theraTRACE™

Products and services

• theraTRACE® Phenotypic screening platform for drug repositioning and indications discovery. The default configuration evaluates compounds across approximately 40 animal models representing 14 broad therapeutic areas using a non-hypothesis-driven multiplexed approach that reduces animal numbers, FTE resource, and test article requirements. Typically completes evaluation across the full suite of models in about 10 weeks.
• opioidTRACE® In vivo pharmacology platform specifically tailored for analgesic therapy research. Examines acute and chronic analgesia, different pain pathways, respiratory depression, gastric motility, and abuse liability. Configurable in higher-throughput screening mode or full characterization mode.
• immuno-theraTRACE™ Oncology platform enabling screening of immune-modulating agents for therapeutic potential across a range of tumor types, including hot and cold tumors, using syngeneic mouse models. Supports high-throughput mode for multiple compounds in smaller groups and lead candidate mode for detailed dose analysis.
• In Vivo Disease Models Catalog of more than 80 validated animal models (rat and mouse) across 14 therapeutic areas including metabolic, oncology, aging, neurology, pain, inflammation, dermatology, cardiovascular, GI, psychiatric, neurological, and neurodegenerative disorders. Custom models and modifications to existing models are also available.
• In Vivo Pharmacology Services Preclinical contract research services evaluating candidate therapeutics in animal models of human disease. Services include study design, execution, data analysis, and interpretive briefs provided by experienced scientific staff. Offered as per-project fee-for-service engagements or long-term FTE-based partnerships.

Quantifiable outcome

• Approximately 1 in 3 compounds screened present with potential new indications
• +7 more outcomes

Named customers24 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core and minor.

• Adhera TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 29 July 2021Melior Pharmaceuticals (sister company) completed a licensing agreement with Adhera Therapeutics for Armesocarb in July 2021. Adhera also entered a letter of intent for acquisition of Armesocarb in June 2021.
• SFA TherapeuticsminorStrategic or Co-development Partner · 24 June 2020Melior Discovery announced a partnership with SFA Therapeutics directed at COVID-19. SFA was involved in grant-directed work for COVID-19 pulmonary therapeutic development.
• NIH/SBIRminorOthers · 11 December 2014Melior Discovery was awarded an SBIR (Small Business Innovation Research) grant for studying the MLR-1023 mechanism of action.
• Bukwang Pharmaceutical Co.coreOEM/ Whitelabel/ Licensing Partner · 4 December 2013Melior licensed its novel diabetes drug MLR-1023 to Bukwang Pharmaceutical Co. in December 2013. This was a major milestone resulting in a partnership that achieved a development milestone payment in October 2014.
• Michael J. Fox FoundationminorOthers · 16 August 2011Melior Discovery was awarded a grant from the Michael J. Fox Foundation for Parkinson's disease research, specifically for studying the MLR-1023 mechanism of action.
• Rett Syndrome Research TrustminorStrategic or Co-development Partner · 30 March 2010Melior announced a collaboration with the Rett Syndrome Research Trust for drug discovery research involving evaluation of compounds in animal models for Rett syndrome.
• AstraZeneca (Research Collaboration)coreStrategic or Co-development Partner · 19 August 2008Melior entered a research collaboration with AstraZeneca focused on in vivo pharmacology studies.
• PfizercoreStrategic or Co-development PartnerMelior entered into a research collaboration with Pfizer (2007) and later a option agreement with Pfizer (2008). Collaboration involved the use of Melior's in vivo pharmacology services and phenotypic screening capabilities.
• MerckcoreStrategic or Co-development PartnerMelior established a collaboration with Merck for in vivo pharmacology services. Merck is also a client for Melior's services and was listed as a trusted partner on the company website.
• AstraZenecacoreStrategic or Co-development PartnerMelior entered into a research collaboration with AstraZeneca (2008). AstraZeneca is listed among Melior's established collaborations alongside Pfizer, Merck, and Johnson & Johnson.
• Johnson & JohnsoncoreStrategic or Co-development PartnerMelior entered into a pharmaceutical collaboration with Johnson & Johnson (2007). J&J is among Melior's established collaborations alongside Pfizer, Merck, and AstraZeneca.
• Top-10 Pharmaceutical Companies (unspecified)coreStrategic or Co-development PartnerMelior's core competence of in vivo pharmacology and high-throughput in vivo screening has involved partnerships with more than half of the top ten pharmaceutical companies since its founding in 2005.
• Christopher Lipinski (Scientific Advisor)coreOthersScientific advisor with expertise in drug discovery and the Lipinski Rule of Five. Christopher Lipinski was named in top ten most influential people in pharma (World Pharmaceutical Frontiers, Pharma 40, 2007).
• Karl Kieburtz (Scientific Advisor)coreOthersKey opinion leader (KOL) in Parkinson's disease who assists in identifying clinically translatable animal models for Parkinson's disease research.
• Zan Fleming (Scientific Advisor)coreOthersKey opinion leader (KOL) representing therapeutic areas including diabetes, assisting in identifying clinically translatable animal models.

Scale indicators15 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Charles River Laboratories: Largest preclinical CRO globally offering in vivo pharmacology, safety assessment, and drug discovery services across all therapeutic areas. Directly comparable to Melior in preclinical efficacy/safety services but with vastly greater scale, geographic reach, and a broader service portfolio.
• Evotec: Global drug discovery CRO offering phenotypic screening, in vivo pharmacology, and drug repositioning services. Directly comparable in drug repositioning and phenotypic screening capabilities, though with much broader integrated discovery platforms.
• WuXi AppTec: Global CRO/CDMO providing comprehensive preclinical research including in vivo pharmacology and animal model services. Comparable in preclinical CRO services with significantly larger scale, integrated discovery-through-manufacturing capabilities, and global footprint.
• Eurofins Discovery: Drug discovery services division of Eurofins offering in vitro and in vivo pharmacology, phenotypic screening, and ADMETox services. Comparable in preclinical drug discovery and screening services with broader integrated offerings.
• Labcorp Drug Development (Fortrea): Major global CRO offering preclinical in vivo pharmacology, safety assessment, and drug discovery services across all therapeutic areas. Comparable in preclinical CRO services with significantly broader portfolio and global scale following its spinout from Labcorp.

Direct peers

• Inotiv: Preclinical CRO specializing in in vivo animal model services, safety assessment, and research models for pharma/biotech. Comparable to Melior in core in vivo pharmacology offerings with a focus on small animal models and preclinical research.
• Pharmaron: Integrated CRO providing in vivo pharmacology, drug discovery, and preclinical research services. Comparable in preclinical efficacy services and in vivo animal model work, with greater global scale across US, UK, and China.
• Reaction Biology: Preclinical CRO offering in vivo and in vitro pharmacology services with a focus on oncology, CNS, and metabolic disease models. Comparable in specialty in vivo pharmacology services for drug discovery clients in similar therapeutic areas.
• Crown Bioscience: Preclinical CRO specializing in oncology and immuno-oncology in vivo models, with translational pharmacology services. Comparable in oncology-focused in vivo pharmacology and immuno-oncology screening platforms (parallel to immuno-theraTRACE™).
• Bionova Scientific: Preclinical CRO providing in vivo pharmacology and efficacy studies for biopharma clients. Comparable in providing in vivo efficacy services to small and mid-sized biopharma, with similar size and customer profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/melior_discover
• LinkedInlinkedin.com/company/melior-discovery

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Melior Discovery